Furthermore, ILT4 blockade displayed synergy with the PD-L1 inhibitor in EGFR wild-type rather than EGFR mutant NSCLC in humanized mouse immunotherapy models. This evidence concerns the gene LILRB2 and non-small cell lung carcinoma.